Advertisement
Screener

Adial Pharmaceuticals, Inc. (ADIL) Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Interests

1.7 / 5 stars · 15/45 Roast Me

Adial Pharmaceuticals, Inc. Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Interests

Adial Pharmaceuticals, Inc. (ADIL) reported Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Interests of $1.73 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.

Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation

us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentEquityInterests · last filed 2024-08-13

  • Adial Pharmaceuticals, Inc. business combination, provisional information, initial accounting incomplete, adjustment, equity interests for the quarter ending 2023-12-31 was $0.00.
  • Adial Pharmaceuticals, Inc. business combination, provisional information, initial accounting incomplete, adjustment, equity interests for the quarter ending 2023-09-30 was $0.00.
  • Adial Pharmaceuticals, Inc. business combination, provisional information, initial accounting incomplete, adjustment, equity interests for fiscal 2023 was $1.73M.
Period endBusiness Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Interests 3 monthBusiness Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Interests 6 monthBusiness Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Interests 9 monthBusiness Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Interests 12 month
2024-06-30$1.73M
10-Q · filed 2024-08-13
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
$0.00
derived: sum of 2 quarters · filed 2024-04-01
$1.73M
10-K · filed 2024-04-01
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-14
$1.73M
10-Q · filed 2023-11-14
2023-06-30$1.73M
10-Q/A · filed 2023-10-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
Scienture Holdings, Inc. (SCNX)United States$0.012B-0.38
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
BIOVIE INC. (BIVI)United States$0.012B
Dare Bioscience, Inc. (DARE)United States$0.011B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
Tempest Therapeutics, Inc. (TPST)United States$0.013B
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36
Moleculin Biotech, Inc. (MBRX)United States$0.011B
MetaVia Inc. (MTVA)United States$0.011B-0.65